Sanofi, in the midst of another of its own leadership shakeups, clearly has been reviewing a lot of resumes lately, and now the company has recommended new members for Medivation Inc.'s board of directors who may support a proposed $9.3bn buyout of the US prostate cancer drug developer.
Pfizer Inc., Amgen Inc., Novartis AG and AstraZeneca PLC – and now also Gilead Sciences...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
